Authors
Latest:
Evaluating the Toxicity Profile of Parsaclisib in Mantle Cell LymphomaAmitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.
Latest:
Case 3: Role of Preoperative Endocrine Therapy in HR+ High-Risk Breast CancerHeather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.
Latest:
Committee Helps Physician's Find Best Options for Patients Through NGSJennifer Marie Suga, MD, discusses how the results from next-generation sequencing tests are assessed to help physicians manage their patients in real-time.
Latest:
Clinical Pearls for the Management of TCR MMAdriana Rossi, MD, provides clinical pearls on the management of triple-class refractory multiple myeloma.
Latest:
Tolerability of Zilovertamab and Ibrutinib in Phase 1/2 Trial of MCLHun Ju Lee, MD, discusses the early results of the dose finding and safety study of zilovertamab plus ibrutinib for patients with mantle cell lymphoma as well as chronic lymphocytic leukemia and marginal zone lymphoma.
Latest:
Creating Solutions for a 'Continual State of Transition' in Cancer CareIn a Peers & Perspectives in Oncology feature article, we focus on the importance of the transition-of-care process for patients with cancer as they move from the inpatient to outpatient setting, as well as between lines of therapy with comments from Marc J. Braunstein, MD, PhD, and Michael Shusterman, MD.
Latest:
Prior ERBT Did Not Increase Hematological Toxicity in Ra-223-Treated mCRPCPrior treatment with external beam radiation therapy did not increase incidence of hematological toxicity relative to the overall population of patients with metastatic castration-resistant prostate cancer treated with radium-223.
Latest:
Mechanism-Driven Science Informs Novel Treatments in Soft Tissue SarcomaVarious combination strategies are being explored in soft tissue sarcomas in efforts to increase efficacy.
Latest:
Examining ESR1 Alterations in HR-Positive Metastatic Breast CancerJamie Brett discusses the similarities and differences between ESR1 mutations and fusions and why they are grouped together.
Latest:
Advice for Clinicians on Treating Patients with Prostate CancerDr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.
Latest:
Practice Changing Updates in the EGFR+ and KRAS+ NSCLC SpaceAndreas Saltos, MD, discusses the current space for patients with non-small cell lung cancer harbording EGFR and KRAS mutations.
Latest:
World Lymphoma Awareness Day: More Drugs, Targets, and Hope in Non-Hodgkin LymphomaLee Greenberger, PhD, evaluates novel immunotherapies in non-Hodgkin lymphoma for World Lymphoma Awareness Day.
Latest:
Follicular Lymphoma: Forecasting Bispecific Antibody Treatment StrategiesClosing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.
Latest:
Key Takeaways Regarding Biomarker Testing for mNSCLCClosing thoughts from a panel of NSCLC experts, with an emphasis on improving access to and utilization of biomarker testing for patients with the disease.
Latest:
Studies in the Hepatocellular Carcinoma Space Leave Unanswered QuestionsAmaia Lujambio Goizueta, PhD, discusses the unanswered questions currently circulating the hepatocellular carcinoma field.
Latest:
Social Determinants of Health Should Be an Integral Component of Cancer Clinical TrialsThe COVID-19 pandemic has highlighted the marvels of rapid technologic advances while spotlighting the social issues that have been evident for decades but ignored and poorly addressed in many cases.
Latest:
The Future of Research in PEComasThe panel shares future areas of research in malignant PEComa that interest them, and how they see the treatment landscape evolving.
Latest:
AFM13 Plus AB-101 to Be Tested in Phase 2 StudyThe ongoing LuminICE phase 2 study demonstrated that AFM13 in combination with AB-101 may hold promise for the treatment of patients with relapsed or refractory CD30-positive lymphomas.
Latest:
Lung Cancer Screening Shown to Significantly Boost 20-Year Survival Rate in PatientsIn an early-intervention lung screening program, patients with lung cancer were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.
Latest:
Discussing Patient Characteristics in ESCC On Ipilimumab/NivolumabKen Kato, MD, PhD, discusses which patient characteristics to look out for when looking to put a patient on the combination of ipilimumab and nivolumab.
Latest:
Improved Safety Measures Mark Newest Treatments in Soft Tissue SarcomaIn early 2020, the treatment paradigm of soft tissue sarcoma had 3 notable advancements with the FDA approving therapies in epithelioid sarcoma, Kaposi sarcoma, and gastrointestinal stromal tumors.
Latest:
Looking Towards the Future of Molecular Testing and Additional Treatment Options for Patients with mNSCLCThe panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
Latest:
Overall Survival Improved With 177 Lu-Dotatate for Patients With Progressive Midgut NETsFinal overall survival and long-term safety results of the phase 3 NETTER-1 trial were presented during the World Congress on Gastrointestinal Cancer 2021.
Latest:
Challenges Hinder Machine Learning's Potential in OncologyJames Zou, PhD, elaborates on some of the challenges associated with machine learning techniques and its utilization in oncology.
Latest:
Management of HR+, HER2- Early-Stage Breast Cancer After DiagnosisPhysicians cover the options for a patient with hormone receptor–positive, HER2-negative, early-stage breast cancer, which course of action they would take, and the data supporting that choice.
Latest:
Real-World Outcomes of Brexu-cel in R/R B-Cell ALLEvandro D. Bezerra, MD, provides real-world data from the CIBMTR Registry, examining the effectiveness of brexucabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
